BUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug

Reuters12-08

BUZZ-<a href="https://laohu8.com/S/FULC">Fulcrum Therapeutics</a> rises after trial data of blood disorder drug

** Shares of drug developer Fulcrum Therapeutics FULC.O jump 49.4% to $13.30 premarket

** Flucrum said on Sunday its experimental drug showed positive results in patients with sickle cell disease from an ongoing 20 dose cohort of an early-stage trial

** Sickle cell disease is an inherited blood disorder that affects the hemoglobin in red blood cells

** In a 12-patient study, the company is testing the safety and efficacy of its experimental drug, pociredir, an oral once-daily HbF inducer

** FULC says every patients in the study experienced a significant rise in fetal hemoglobin (HbF) levels after treatment

** Company plans to re-engage with the FDA in H1 2026

** RBC Capital Markets says it remains on the sidelines, awaiting further regulatory clarity around Fulcrum Therapeutics' development plans

** "We think it will be important to see... whether regulators will allow FULC to move directly into a pivotal trial or ask for an intermediate Phase II trial first" brokerage adds

** As of last close, stock was up 89.4% YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589353100?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589353100","market":"fut","top_or_hot":-1,"title":"BUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> rises after trial data of blood disorder drug</title></head><body><p>** Shares of drug developer Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>FULC.O</span> jump 49.4% to $13.30 premarket </p><p>** Flucrum said on Sunday its experimental drug showed positive results in patients with sickle cell disease from an ongoing 20 dose cohort of an early-stage trial </p><p>** Sickle cell disease is an inherited blood disorder that affects the hemoglobin in red blood cells</p><p>** In a 12-patient study, the company is testing the safety and efficacy of its experimental drug, pociredir, an oral once-daily HbF inducer</p><p>** FULC says every patients in the study experienced a significant rise in fetal hemoglobin (HbF) levels after treatment</p><p>** Company plans to re-engage with the FDA in H1 2026</p><p>** RBC Capital Markets says it remains on the sidelines, awaiting further regulatory clarity around Fulcrum Therapeutics' development plans</p><p>** \"We think it will be important to see... whether regulators will allow FULC to move directly into a pivotal trial or ask for an intermediate Phase II trial first\" brokerage adds</p><p>** As of last close, stock was up 89.4% YTD </p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> rises after trial data of blood disorder drug</title></head><body><p>** Shares of drug developer Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>FULC.O</span> jump 49.4% to $13.30 premarket </p><p>** Flucrum said on Sunday its experimental drug showed positive results in patients with sickle cell disease from an ongoing 20 dose cohort of an early-stage trial </p><p>** Sickle cell disease is an inherited blood disorder that affects the hemoglobin in red blood cells</p><p>** In a 12-patient study, the company is testing the safety and efficacy of its experimental drug, pociredir, an oral once-daily HbF inducer</p><p>** FULC says every patients in the study experienced a significant rise in fetal hemoglobin (HbF) levels after treatment</p><p>** Company plans to re-engage with the FDA in H1 2026</p><p>** RBC Capital Markets says it remains on the sidelines, awaiting further regulatory clarity around Fulcrum Therapeutics' development plans</p><p>** \"We think it will be important to see... whether regulators will allow FULC to move directly into a pivotal trial or ask for an intermediate Phase II trial first\" brokerage adds</p><p>** As of last close, stock was up 89.4% YTD </p><p> (Reporting by Siddhi Mahatole)</p><p> ((siddhi.mahatole@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FULC","symbol_name":"Fulcrum Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE0X1:1","article_id":"2589353100","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589353100","pubTimestamp":1765199557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug** Shares of drug developer Fulcrum Therapeutics FULC.O jump 49.4% to $13.30 premarket ** Flucrum said on Sunday its experimental drug showed positive results in patients with sickle cell disease from an ongoing 20 dose cohort of an early-stage trial ** Sickle cell disease is an inherited blood disorder that affects the hemoglobin in red blood cells** In a 12-patient study, the company is testing the safety and efficacy of its experimental drug, pociredir, an oral once-daily HbF inducer** FULC says every patients in the study experienced a significant rise in fetal hemoglobin  levels after treatment** Company plans to re-engage with the FDA in H1 2026** RBC Capital Markets says it remains on the sidelines, awaiting further regulatory clarity around Fulcrum Therapeutics' development plans** \"We think it will be important to see... whether regulators will allow FULC to move directly into a pivotal trial or ask for an ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FULC":"Fulcrum Therapeutics","BK4007":"制药"},"translate_title":"血液疾病药物试验数据公布后，BUZZ-Fulcrum Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":0.9},"content_text":"BUZZ-Fulcrum Therapeutics rises after trial data of blood disorder drug** Shares of drug developer Fulcrum Therapeutics FULC.O jump 49.4% to $13.30 premarket ** Flucrum said on Sunday its experimental drug showed positive results in patients with sickle cell disease from an ongoing 20 dose cohort of an early-stage trial ** Sickle cell disease is an inherited blood disorder that affects the hemoglobin in red blood cells** In a 12-patient study, the company is testing the safety and efficacy of its experimental drug, pociredir, an oral once-daily HbF inducer** FULC says every patients in the study experienced a significant rise in fetal hemoglobin (HbF) levels after treatment** Company plans to re-engage with the FDA in H1 2026** RBC Capital Markets says it remains on the sidelines, awaiting further regulatory clarity around Fulcrum Therapeutics' development plans** \"We think it will be important to see... whether regulators will allow FULC to move directly into a pivotal trial or ask for an intermediate Phase II trial first\" brokerage adds** As of last close, stock was up 89.4% YTD  (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589353100","isCrawlerRequest":true}